JP5937321B2 - Skin preparation - Google Patents
Skin preparation Download PDFInfo
- Publication number
- JP5937321B2 JP5937321B2 JP2011210419A JP2011210419A JP5937321B2 JP 5937321 B2 JP5937321 B2 JP 5937321B2 JP 2011210419 A JP2011210419 A JP 2011210419A JP 2011210419 A JP2011210419 A JP 2011210419A JP 5937321 B2 JP5937321 B2 JP 5937321B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- component
- external preparation
- ether
- glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims description 54
- -1 ethyleneoxy group Chemical group 0.000 claims description 35
- 238000004519 manufacturing process Methods 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 125000004432 carbon atom Chemical group C* 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 15
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- 239000004094 surface-active agent Substances 0.000 claims description 14
- 210000004761 scalp Anatomy 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 9
- 230000000699 topical effect Effects 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 101001047889 Staphylococcus aureus Delta-hemolysin Proteins 0.000 claims 1
- 244000005700 microbiome Species 0.000 description 29
- 239000003053 toxin Substances 0.000 description 27
- 231100000765 toxin Toxicity 0.000 description 27
- 108700012359 toxins Proteins 0.000 description 27
- 235000014113 dietary fatty acids Nutrition 0.000 description 25
- 229930195729 fatty acid Natural products 0.000 description 25
- 239000000194 fatty acid Substances 0.000 description 25
- 101710121036 Delta-hemolysin Proteins 0.000 description 20
- 239000000047 product Substances 0.000 description 18
- 208000003251 Pruritus Diseases 0.000 description 17
- 150000004665 fatty acids Chemical class 0.000 description 16
- 230000000844 anti-bacterial effect Effects 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 8
- 150000005215 alkyl ethers Chemical class 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 150000002430 hydrocarbons Chemical group 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- XFRVVPUIAFSTFO-UHFFFAOYSA-N 1-Tridecanol Chemical compound CCCCCCCCCCCCCO XFRVVPUIAFSTFO-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- GOQYKNQRPGWPLP-UHFFFAOYSA-N heptadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 7
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 7
- FVDRFBGMOWJEOR-UHFFFAOYSA-N hexadecan-2-ol Chemical compound CCCCCCCCCCCCCCC(C)O FVDRFBGMOWJEOR-UHFFFAOYSA-N 0.000 description 7
- 230000007803 itching Effects 0.000 description 7
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 7
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 7
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 6
- FKMHSNTVILORFA-UHFFFAOYSA-N 2-[2-(2-dodecoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCO FKMHSNTVILORFA-UHFFFAOYSA-N 0.000 description 6
- 206010012438 Dermatitis atopic Diseases 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 201000008937 atopic dermatitis Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 5
- 231100000757 Microbial toxin Toxicity 0.000 description 5
- 239000003899 bactericide agent Substances 0.000 description 5
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 244000000010 microbial pathogen Species 0.000 description 5
- ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 5
- REIUXOLGHVXAEO-UHFFFAOYSA-N pentadecan-1-ol Chemical compound CCCCCCCCCCCCCCCO REIUXOLGHVXAEO-UHFFFAOYSA-N 0.000 description 5
- 239000001974 tryptic soy broth Substances 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- UKODLHVFJRCQME-UHFFFAOYSA-N 2-[2-(2-decoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCCCCCOCCOCCOCCO UKODLHVFJRCQME-UHFFFAOYSA-N 0.000 description 4
- NBPXCCCUFZBDQE-UHFFFAOYSA-N 2-[2-(2-tetradecoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCOCCOCCOCCO NBPXCCCUFZBDQE-UHFFFAOYSA-N 0.000 description 4
- ASMWIUUCZFNLHL-UHFFFAOYSA-N 2-[2-[2-(2-decoxyethoxy)ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCOCCOCCOCCOCCO ASMWIUUCZFNLHL-UHFFFAOYSA-N 0.000 description 4
- QAXPOSPGRHYIHE-UHFFFAOYSA-N 2-[2-[2-[2-(2-decoxyethoxy)ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCOCCOCCOCCOCCOCCO QAXPOSPGRHYIHE-UHFFFAOYSA-N 0.000 description 4
- KXGOCXPKKMVOSB-UHFFFAOYSA-N 2-[2-[2-[2-(2-tetradecoxyethoxy)ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCOCCOCCOCCOCCOCCO KXGOCXPKKMVOSB-UHFFFAOYSA-N 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 206010012442 Dermatitis contact Diseases 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 229960003237 betaine Drugs 0.000 description 4
- 239000003240 coconut oil Substances 0.000 description 4
- 235000019864 coconut oil Nutrition 0.000 description 4
- 208000010247 contact dermatitis Diseases 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- LAPRIVJANDLWOK-UHFFFAOYSA-N laureth-5 Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCO LAPRIVJANDLWOK-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- HKOLRKVMHVYNGG-UHFFFAOYSA-N tridecan-2-ol Natural products CCCCCCCCCCCC(C)O HKOLRKVMHVYNGG-UHFFFAOYSA-N 0.000 description 4
- UVNSFSOKRSZVEZ-UHFFFAOYSA-N 2-(2-decoxyethoxy)ethanol Chemical compound CCCCCCCCCCOCCOCCO UVNSFSOKRSZVEZ-UHFFFAOYSA-N 0.000 description 3
- AZLWQVJVINEILY-UHFFFAOYSA-N 2-(2-dodecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCOCCOCCO AZLWQVJVINEILY-UHFFFAOYSA-N 0.000 description 3
- OARYCGKAYBBHAM-UHFFFAOYSA-N 2-[2-[2-(2-tetradecoxyethoxy)ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCOCCOCCOCCOCCO OARYCGKAYBBHAM-UHFFFAOYSA-N 0.000 description 3
- OJCFEGKCRWEVSN-UHFFFAOYSA-N 2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCO OJCFEGKCRWEVSN-UHFFFAOYSA-N 0.000 description 3
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 3
- WMPGRAUYWYBJKX-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO WMPGRAUYWYBJKX-UHFFFAOYSA-N 0.000 description 3
- CMOAVXMJUDBIST-UHFFFAOYSA-N 3,6,9,12,15,18-Hexaoxadotriacontan-1-ol Chemical compound CCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCO CMOAVXMJUDBIST-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000003945 anionic surfactant Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- YYELLDKEOUKVIQ-UHFFFAOYSA-N octaethyleneglycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCO YYELLDKEOUKVIQ-UHFFFAOYSA-N 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108010050327 trypticase-soy broth Proteins 0.000 description 3
- KJIOQYGWTQBHNH-UHFFFAOYSA-N undecanol Chemical compound CCCCCCCCCCCO KJIOQYGWTQBHNH-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MLRYPOCSLBIUHY-ZHACJKMWSA-N (e)-dodec-2-en-1-ol Chemical compound CCCCCCCCC\C=C\CO MLRYPOCSLBIUHY-ZHACJKMWSA-N 0.000 description 2
- 239000005968 1-Decanol Substances 0.000 description 2
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 2
- UJMHIOBAHVUDGS-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-(2-decoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCO UJMHIOBAHVUDGS-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- NGDNVOAEIVQRFH-UHFFFAOYSA-N 2-nonanol Chemical compound CCCCCCCC(C)O NGDNVOAEIVQRFH-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- QVFOGJXHRGAFSH-UHFFFAOYSA-N acetic acid;1-dodecoxydodecane Chemical compound CC(O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC QVFOGJXHRGAFSH-UHFFFAOYSA-N 0.000 description 2
- 150000008051 alkyl sulfates Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 230000009422 growth inhibiting effect Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 2
- 239000003346 palm kernel oil Substances 0.000 description 2
- 235000019865 palm kernel oil Nutrition 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- NUBWFSDCZULDCI-BLHCBFLLSA-N (2E,4E)-2,4-Decadien-1-ol Chemical compound CCCCC\C=C\C=C\CO NUBWFSDCZULDCI-BLHCBFLLSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical class C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- LPMBTLLQQJBUOO-KTKRTIGZSA-N (z)-n,n-bis(2-hydroxyethyl)octadec-9-enamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N(CCO)CCO LPMBTLLQQJBUOO-KTKRTIGZSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- HANWHVWXFQSQGJ-UHFFFAOYSA-N 1-tetradecoxytetradecane Chemical compound CCCCCCCCCCCCCCOCCCCCCCCCCCCCC HANWHVWXFQSQGJ-UHFFFAOYSA-N 0.000 description 1
- WNRNXKWTIJWZFQ-UHFFFAOYSA-N 2-(2-tetradecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCOCCOCCO WNRNXKWTIJWZFQ-UHFFFAOYSA-N 0.000 description 1
- ACUZDYFTRHEKOS-SNVBAGLBSA-N 2-Decanol Natural products CCCCCCCC[C@@H](C)O ACUZDYFTRHEKOS-SNVBAGLBSA-N 0.000 description 1
- NHHAZFYVKWSFIR-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-(2-tetradecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCO NHHAZFYVKWSFIR-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101710092462 Alpha-hemolysin Proteins 0.000 description 1
- 101710197219 Alpha-toxin Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- UJSVDXWCNAFDFY-UHFFFAOYSA-N C(CCCCCCCCC)OCCO.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C Chemical compound C(CCCCCCCCC)OCCO.C=C.C=C.C=C.C=C.C=C.C=C.C=C.C=C UJSVDXWCNAFDFY-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- QZXSMBBFBXPQHI-UHFFFAOYSA-N N-(dodecanoyl)ethanolamine Chemical compound CCCCCCCCCCCC(=O)NCCO QZXSMBBFBXPQHI-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 101710124951 Phospholipase C Proteins 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000344861 Staphylococcus aureus subsp. aureus NCTC 8325 Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001294 alanine derivatives Chemical class 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 239000002776 alpha toxin Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- JUWXVJKQNKKRLD-UHFFFAOYSA-N dec-3-yne Chemical compound CCCCCCC#CCC JUWXVJKQNKKRLD-UHFFFAOYSA-N 0.000 description 1
- ACUZDYFTRHEKOS-UHFFFAOYSA-N decan-2-ol Chemical compound CCCCCCCCC(C)O ACUZDYFTRHEKOS-UHFFFAOYSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 229940031957 lauric acid diethanolamide Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- ONHFWHCMZAJCFB-UHFFFAOYSA-N myristamine oxide Chemical compound CCCCCCCCCCCCCC[N+](C)(C)[O-] ONHFWHCMZAJCFB-UHFFFAOYSA-N 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- GGOZGYRTNQBSSA-UHFFFAOYSA-N pyridine-2,3-diol Chemical class OC1=CC=CN=C1O GGOZGYRTNQBSSA-UHFFFAOYSA-N 0.000 description 1
- 229960001141 pyrithione zinc Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- BRGJIIMZXMWMCC-UHFFFAOYSA-N tetradecan-2-ol Chemical compound CCCCCCCCCCCCC(C)O BRGJIIMZXMWMCC-UHFFFAOYSA-N 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002569 water oil cream Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は身体に適用する化粧品、医薬部外品又は医薬品等の皮膚外用剤に関し、より詳細には、微生物の毒素産生抑制に用いる皮膚外用剤、すなわち、皮膚表面の微生物が起因となる皮膚トラブル、例えば、頭皮のかゆみあるいは創傷治癒遅延やアトピー性皮膚炎、皮膚掻痒症、接触皮膚炎などの皮膚疾患の悪化を予防、改善し、かつ皮膚にやさしい皮膚外用剤に関するものである。 The present invention relates to a skin external preparation such as cosmetics, quasi-drugs or pharmaceuticals applied to the body, and more specifically, a skin external preparation used for the suppression of microbial toxin production, that is, skin troubles caused by microorganisms on the skin surface. For example, the present invention relates to an external preparation for skin which prevents or improves exacerbation of skin diseases such as itching of the scalp or wound healing delay, atopic dermatitis, skin pruritus and contact dermatitis, and is gentle to the skin.
皮膚表面に生息する微生物が産生する毒素により、頭皮のかゆみあるいは創傷治癒遅延やアトピー性皮膚炎、皮膚掻痒症、接触皮膚炎の悪化などの様々なトラブルが引き起こされる。 Toxins produced by microorganisms that inhabit the skin surface cause various troubles such as itchy scalp or delayed wound healing, atopic dermatitis, skin pruritus, and worsening contact dermatitis.
頭皮のかゆみを防止、軽減するために、塩化ベンザルコニウム、塩化ベンゼトニウム、塩化セチルピリジニウム、イソプロピルメチルフェノール、ピリチオン亜鉛、ヒドロキシピリドン誘導体、イオウ、クロルヘキシジン等の殺菌剤を毛髪化粧料に配合することが知られている（特許文献１）。また、創傷やアトピー性皮膚炎などの皮膚疾患の悪化を予防または改善するために、１−オクタノールなどを皮膚外用剤に配合することが知られている（特許文献２）。また、抗炎症剤、炭素数１２〜２０の不飽和脂肪族アルコール、保存剤、炭素数１〜６の一価低級アルコールを含有する均一系水性皮膚外用剤組成物が知られている（特許文献３）。 In order to prevent and reduce itching of the scalp, bactericides such as benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, isopropylmethylphenol, pyrithione zinc, hydroxypyridone derivatives, sulfur and chlorhexidine may be added to hair cosmetics. Known (Patent Document 1). In addition, in order to prevent or improve deterioration of skin diseases such as wounds and atopic dermatitis, it is known to add 1-octanol or the like to an external preparation for skin (Patent Document 2). Further, a homogeneous aqueous skin external preparation composition containing an anti-inflammatory agent, an unsaturated aliphatic alcohol having 12 to 20 carbon atoms, a preservative, and a monovalent lower alcohol having 1 to 6 carbon atoms is known (Patent Document). 3).
特許文献１に代表される、殺菌的アプローチは、一時的な殺菌効果はあるものの、経時的な毒素産生抑制効果、例えば日単位での毒素産生抑制効果には問題があり、結果的に長期にわたる毒素の産生は抑制できていなかった。同様に特許文献２記載の１−オクタノール等を利用した手法も抗菌的に微生物の増殖を抑制する傾向があるため、一時的な効果はあるものの日単位での毒素産生抑制効果には問題があり、結果的に長期にわたる毒素の産生は抑制できていなかった。上述した問題以外にこれらの剤を用いたアプローチは皮膚（人体）への刺激性が高く、また病原微生物だけでなく生体防御としての役割を果たしている皮膚常在菌（表皮ブドウ球菌など）に対しても作用してしまうので、皮膚トラブル、例えば頭皮のかゆみあるいは創傷治癒遅延やアトピー性皮膚炎などの皮膚疾患の悪化につながる。更にこれらの手法は薬剤耐性菌を出現させる原因となることも知られており、いまだ効果としては不十分である。 Although the bactericidal approach represented by Patent Document 1 has a temporary bactericidal effect, there is a problem with the time-dependent toxin production inhibitory effect, for example, the toxin production inhibitory effect on a daily basis. Toxin production could not be suppressed. Similarly, the technique using 1-octanol or the like described in Patent Document 2 also tends to suppress the growth of microorganisms in an antibacterial manner. Therefore, although there is a temporary effect, there is a problem with the daily toxin production inhibitory effect. As a result, long-term toxin production could not be suppressed. In addition to the problems described above, the approach using these agents is highly irritating to the skin (human body), and against not only pathogenic microorganisms but also skin resident bacteria (such as Staphylococcus epidermidis) that play a role as biological defenses. May cause skin troubles such as itching of the scalp or worsening of skin diseases such as delayed wound healing and atopic dermatitis. Furthermore, these methods are known to cause drug-resistant bacteria to appear, and are still insufficient in effect.
本発明の課題は、微生物由来の毒素産生を抑制することにより、微生物による皮膚表面での様々なトラブルを抑制する皮膚外用剤を提供することである。 The subject of this invention is providing the skin external preparation which suppresses various troubles on the skin surface by microorganisms by suppressing the toxin production derived from microorganisms.
本発明は、下記一般式（ａ１）で表される化合物及び一般式（ａ２）で表される化合物から選ばれる１種以上の化合物（Ａ）を０．００１〜５重量％、並びに、炭素数２〜３の１価アルコール（Ｂ）を２５〜８５重量％含有する、微生物の毒素産生抑制に用いる皮膚外用剤に関する。
Ｒ1−ＯＨ （ａ１）
（式中、Ｒ1は炭素数９〜１８の炭化水素基を示す。）
Ｒ2−Ｏ−（ＥＯ）n−Ｈ （ａ２）
（式中、Ｒ2は炭素数８〜１８の炭化水素基を示し、ＥＯはエチレンオキシ基を示し、ｎは１〜１５の整数を示す。）
In the present invention, 0.001 to 5% by weight of one or more compounds (A) selected from the compound represented by the following general formula (a1) and the compound represented by the general formula (a2), and the number of carbon atoms. It is related with the skin external preparation used for suppression of the toxin production of microorganisms containing 25-85 weight% of 2-3 monohydric alcohol (B).
R 1 —OH (a1)
(In the formula, R 1 represents a hydrocarbon group having 9 to 18 carbon atoms.)
R 2 —O— (EO) n —H (a2)
(In the formula, R 2 represents a hydrocarbon group having 8 to 18 carbon atoms, EO represents an ethyleneoxy group, and n represents an integer of 1 to 15).
また、本発明は、上記一般式（ａ１）で表される化合物及び一般式（ａ２）で表される化合物から選ばれる１種以上の化合物（Ａ）〔以下、成分（Ａ）という〕を０．００１〜５重量％、並びに、炭素数２〜３の１価アルコール（Ｂ）〔以下、成分（Ｂ）という〕を２５〜８５重量％含有する皮膚外用剤による、皮膚上の微生物の毒素産生抑制方法に関する。 In addition, the present invention provides one or more compounds (A) [hereinafter referred to as component (A)] selected from the compound represented by the general formula (a1) and the compound represented by the general formula (a2). Production of microbial toxins on the skin by an external preparation for skin containing 25 to 85% by weight of 0.001 to 5% by weight and monohydric alcohol (B) having 2 to 3 carbon atoms (hereinafter referred to as component (B)) It relates to a suppression method.
本発明によれば、皮膚上の微生物が産生する毒素を抑制し、微生物による皮膚表面での様々なトラブルを抑制することができる。すなわち、頭皮のかゆみ、創傷治癒遅延あるいはアトピー性皮膚炎、皮膚掻痒症、接触皮膚炎などの皮膚疾患の悪化などの微生物由来の皮膚トラブルを軽減、抑制することができる。一般的な殺菌剤が適用直後の殺菌力により短期的な効果を得ているのに対し、本発明の皮膚外用剤は、適用後、経時的に微生物の毒素産生を抑制できるため、皮膚トラブルの軽減、抑制効果の持続性に優れる。 ADVANTAGE OF THE INVENTION According to this invention, the toxin which the microorganisms on skin produce can be suppressed and various troubles on the skin surface by microorganisms can be suppressed. That is, it is possible to reduce or suppress skin troubles caused by microorganisms such as itching of the scalp, delayed wound healing, or worsening skin diseases such as atopic dermatitis, dermatitis, and contact dermatitis. Whereas a general bactericidal agent has a short-term effect due to the bactericidal power immediately after application, the topical skin preparation of the present invention can suppress the production of microbial toxins over time after application. Excellent sustainability of reduction and suppression effect.
＜成分（Ａ）＞
本発明の方法に皮膚外用剤は、成分（Ａ）として、下記一般式（ａ１）で表される化合物及び一般式（ａ２）で表される化合物から選ばれる１種以上の化合物を含有する。
Ｒ1−ＯＨ （ａ１）
（式中、Ｒ1は炭素数９〜１８の炭化水素基、好ましくは炭素数９〜１８の直鎖又は分岐鎖のアルキル基又はアルケニル基を示す。）
Ｒ2−Ｏ−（ＥＯ）n−Ｈ （ａ２）
（式中、Ｒ2は炭素数８〜１８の炭化水素基、好ましくは炭素数８〜１８の直鎖又は分岐鎖のアルキル基又はアルケニル基を示し、ＥＯはエチレンオキシ基を示し、ｎは１〜１５の整数を示す。）
<Component (A)>
In the method of the present invention, the external preparation for skin contains at least one compound selected from the compound represented by the following general formula (a1) and the compound represented by the general formula (a2) as the component (A).
R 1 —OH (a1)
(In the formula, R 1 represents a hydrocarbon group having 9 to 18 carbon atoms, preferably a linear or branched alkyl group or alkenyl group having 9 to 18 carbon atoms.)
R 2 —O— (EO) n —H (a2)
(In the formula, R 2 represents a hydrocarbon group having 8 to 18 carbon atoms, preferably a linear or branched alkyl group or alkenyl group having 8 to 18 carbon atoms, EO represents an ethyleneoxy group, and n represents 1 Represents an integer of ~ 15.)
一般式（ａ１）中、Ｒ1で示される炭化水素基は、直鎖でも分岐鎖でもよいが直鎖が好ましい。また、飽和でも不飽和でもよいが飽和が好ましい。よって、Ｒ1は、皮膚上の微生物の毒素産生抑制の観点から、直鎖アルキル基が好ましい。Ｒ1は、炭素数９〜１０または１３〜１８のものが好ましく、更に炭素数１３、１６または１７のものが、毒素産生抑制効果が優れており好ましい。 In general formula (a1), the hydrocarbon group represented by R 1 may be linear or branched, but is preferably linear. Moreover, although saturation or unsaturated may be sufficient, saturation is preferable. Therefore, R 1 is preferably a straight-chain alkyl group from the viewpoint of suppression of microbial toxin production on the skin. R 1 preferably has 9 to 10 or 13 to 18 carbon atoms, and more preferably has 13 to 16 or 17 carbon atoms because of its excellent inhibitory effect on toxin production.
一般式（ａ２）中、Ｒ2で示される炭化水素基は、直鎖でも分岐鎖でもよいが直鎖が好ましい。また、飽和でも不飽和でもよいが飽和が好ましい。よって、Ｒ2は、皮膚上の微生物の毒素産生抑制の観点から、直鎖アルキル基が好ましい。Ｒ2は炭素数１２のものが、毒素産生抑制効果が優れており好ましい。また、ＥＯで示されるエチレンオキシ基の数ｎは、毒素産生抑制効果の観点から、２〜１２の整数が好ましく、３〜６の整数がより好ましい。 In general formula (a2), the hydrocarbon group represented by R 2 may be linear or branched, but is preferably linear. Moreover, although saturation or unsaturated may be sufficient, saturation is preferable. Therefore, R 2 is preferably a straight-chain alkyl group from the viewpoint of inhibiting microbial toxin production on the skin. R 2 having 12 carbon atoms is preferred because of its excellent effect of inhibiting toxin production. In addition, the number n of ethyleneoxy groups represented by EO is preferably an integer of 2 to 12, more preferably an integer of 3 to 6, from the viewpoint of the toxin production inhibitory effect.
一般式（ａ１）で表される化合物としては、毒素産生抑制効果の観点から、１−ノナノール、２−ノナノール、１−デカノール、２−デカノール、２，４−デカジエン−１−オール、３−デシン−１−オール、１−トリデカノール、２−トリデカノール、１−テトラデカノール（ミリスチルアルコール）、２−テトラデカノール、１−ペンタデカノール、１−ヘキサデカノール、２−ヘキサデカノール、１−ヘプタデカノール、１−オクタデカノールが好ましく、１−トリデカノール、２−トリデカノール、１−ヘキサデカノール、２−ヘキサデカノール、１−ヘプタデカノールがより好ましい。 The compounds represented by the general formula (a1) include 1-nonanol, 2-nonanol, 1-decanol, 2-decanol, 2,4-decadien-1-ol, 3-decyne from the viewpoint of the toxin production inhibitory effect. -1-ol, 1-tridecanol, 2-tridecanol, 1-tetradecanol (myristyl alcohol), 2-tetradecanol, 1-pentadecanol, 1-hexadecanol, 2-hexadecanol, 1-hepta Decanol and 1-octadecanol are preferable, and 1-tridecanol, 2-tridecanol, 1-hexadecanol, 2-hexadecanol and 1-heptadecanol are more preferable.
また、一般式（ａ２）で表される化合物としては、毒素産生抑制効果の観点から、ジエチレングリコールモノデシルエーテル、トリエチレングリコールモノデシルエーテル、テトラエチレングリコールモノデシルエーテル、ペンタエチレングリコールモノデシルエーテル、オクタエチレングリコールモノデシルエーテル、ジエチレングリコールモノドデシルエーテル、トリエチレングリコールモノドデシルエーテル、テトラエチレングリコールモノドデシルエーテル、ペンタエチレングリコールモノドデシルエーテル、ヘキサエチレングリコールモノドデシルエーテル、ヘプタエチレングリコールモノドデシルエーテル、オクタエチレングリコールモノドデシルエーテル、ドデカエチレングリコールモノドデシルエーテル、ジエチレングリコールモノテトラデシルエーテル、トリエチレングリコールモノテトラデシルエーテル、テトラエチレングリコールモノテトラデシルエーテル、ペンタエチレングリコールモノテトラデシルエーテル、ヘキサエチレングリコールモノテトラデシルエーテル、オクタエチレングリコールモノテトラデシルエーテルが好ましく、トリエチレングリコールモノデシルエーテル、テトラエチレングリコールモノデシルエーテル、ペンタエチレングリコールモノデシルエーテル、トリエチレングリコールモノドデシルエーテル、テトラエチレングリコールモノドデシルエーテル、ペンタエチレングリコールモノドデシルエーテル、ヘキサエチレングリコールモノドデシルエーテル、トリエチレングリコールモノテトラデシルエーテル、テトラエチレングリコールモノテトラデシルエーテル、ペンタエチレングリコールモノテトラデシルエーテル、ヘキサエチレングリコールモノテトラデシルエーテルがより好ましい。 Moreover, as a compound represented by general formula (a2), from the viewpoint of the toxin production inhibitory effect, diethylene glycol monodecyl ether, triethylene glycol monodecyl ether, tetraethylene glycol monodecyl ether, pentaethylene glycol monodecyl ether, octaethylene Ethylene glycol monodecyl ether, diethylene glycol monododecyl ether, triethylene glycol monododecyl ether, tetraethylene glycol monododecyl ether, pentaethylene glycol monododecyl ether, hexaethylene glycol monododecyl ether, heptaethylene glycol monododecyl ether, octaethylene glycol mono Dodecyl ether, dodecaethylene glycol monododecyl ether, diethylene glycol Monotetradecyl ether, triethylene glycol monotetradecyl ether, tetraethylene glycol monotetradecyl ether, pentaethylene glycol monotetradecyl ether, hexaethylene glycol monotetradecyl ether, octaethylene glycol monotetradecyl ether are preferred, triethylene glycol Monodecyl ether, tetraethylene glycol monodecyl ether, pentaethylene glycol monodecyl ether, triethylene glycol monododecyl ether, tetraethylene glycol monododecyl ether, pentaethylene glycol monododecyl ether, hexaethylene glycol monododecyl ether, triethylene glycol mono Tetradecyl ether, tetraethylene glycol Over mono tetradecyl ether, pentaethylene glycol monotetradecyl ether, hexaethylene glycol monotetradecyl ether are more preferable.
本発明において、皮膚外用剤中の成分（Ａ）の含有量は、優れた毒素産生抑制効果を得る点から０．００１〜５重量％であるが、毒素産生抑制効果の点から０．００５〜０．５重量％が好ましく、更に０．０１〜０．１重量％が好ましい。 In the present invention, the content of the component (A) in the external preparation for skin is 0.001 to 5% by weight from the viewpoint of obtaining an excellent toxin production inhibitory effect, but 0.005 to 0.005 from the viewpoint of the toxin production inhibitory effect. 0.5% by weight is preferable, and further 0.01 to 0.1% by weight is preferable.
＜成分（Ｂ）＞
本発明の皮膚外用剤は、成分（Ｂ）として、本発明の成分（Ａ）を対象物に均等に適用する観点から、炭素数２〜３の１価アルコールを含有する。成分（Ｂ）としては、エタノール、プロパノール、イソプロパノールが挙げられる。皮膚刺激性の観点から、エタノールおよびイソプロパノールが好ましく、特に、エタノールが好ましい。
<Component (B)>
The skin external preparation of this invention contains C1-C3 monohydric alcohol from a viewpoint of applying the component (A) of this invention to a target object as a component (B) equally. Examples of the component (B) include ethanol, propanol, and isopropanol. From the viewpoint of skin irritation, ethanol and isopropanol are preferable, and ethanol is particularly preferable.
本発明において、皮膚外用剤中の成分（Ｂ）の含有量は、成分（Ａ）の溶解性と蒸発速度の観点から２０〜８５重量％であるが、成分（Ａ）の溶解性の観点から２５〜８０重量％が好ましく、更に３０〜７５重量％が好ましい。 In the present invention, the content of the component (B) in the external preparation for skin is 20 to 85% by weight from the viewpoint of the solubility of the component (A) and the evaporation rate, but from the viewpoint of the solubility of the component (A). It is preferably 25 to 80% by weight, more preferably 30 to 75% by weight.
＜成分（Ｃ）＞
本発明の皮膚外用剤は、成分（Ａ）を分散、可溶化又は乳化するために、（Ａ）以外の界面活性剤、（Ａ）以外の溶剤、及び、（Ｂ）以外の溶剤から選ばれる成分（Ｃ）を配合してもよい。
<Ingredient (C)>
The skin external preparation of the present invention is selected from surfactants other than (A), solvents other than (A), and solvents other than (B) in order to disperse, solubilize or emulsify component (A). You may mix | blend a component (C).
成分（Ｃ）として用いる界面活性剤の種類は特に限定されず、陰イオン界面活性剤、非イオン界面活性剤、両性界面活性剤の何れでもよいが、乳化・分散・可溶化性能の観点から、界面活性剤の中で陰イオン界面活性剤又は非イオン界面活性剤を用いることが好ましい。 The type of the surfactant used as the component (C) is not particularly limited and may be any of an anionic surfactant, a nonionic surfactant, and an amphoteric surfactant. From the viewpoint of emulsification / dispersion / solubilization performance, Among the surfactants, an anionic surfactant or a nonionic surfactant is preferably used.
陰イオン界面活性剤としては、硫酸系、スルホン酸系、カルボン酸系、リン酸系及びアミノ酸系のものが好ましく、例えばアルキル硫酸塩、ポリオキシアルキレンアルキルエーテル硫酸塩、ポリオキシアルキレンアルケニルエーテル硫酸塩、スルホコハク酸アルキルエステル塩、ポリオキシアルキレンスルホコハク酸アルキルエステル塩、ポリオキシアルキレンアルキルフェニルエーテル硫酸塩、アルカンスルホン酸塩、アシルイセチオネート、アシルメチルタウレート、高級脂肪酸塩、ポリオキシアルキレンアルキルエーテル酢酸塩、アルキルリン酸塩、ポリオキシアルキレンアルキルエーテルリン酸塩、アシルグルタミン酸塩、アラニン誘導体、グリシン誘導体、アルギニン誘導体等が挙げられる。これらのうち、ポリオキシエチレンアルキルエーテル硫酸塩、ポリオキシエチレンアルケニルエーテル硫酸塩、アルキル硫酸塩、高級脂肪酸塩、ポリオキシアルキレンアルキルエーテル酢酸塩、アルキルリン酸塩、ポリオキシアルキレンアルキルエーテルリン酸塩が好ましい。 As the anionic surfactant, those of sulfuric acid type, sulfonic acid type, carboxylic acid type, phosphoric acid type and amino acid type are preferable, for example, alkyl sulfate, polyoxyalkylene alkyl ether sulfate, polyoxyalkylene alkenyl ether sulfate. , Sulfosuccinic acid alkyl ester salt, polyoxyalkylene sulfosuccinic acid alkyl ester salt, polyoxyalkylene alkyl phenyl ether sulfate, alkane sulfonate, acyl isethionate, acylmethyl taurate, higher fatty acid salt, polyoxyalkylene alkyl ether acetic acid Examples thereof include salts, alkyl phosphates, polyoxyalkylene alkyl ether phosphates, acyl glutamates, alanine derivatives, glycine derivatives, and arginine derivatives. Among these, polyoxyethylene alkyl ether sulfate, polyoxyethylene alkenyl ether sulfate, alkyl sulfate, higher fatty acid salt, polyoxyalkylene alkyl ether acetate, alkyl phosphate, polyoxyalkylene alkyl ether phosphate preferable.
非イオン界面活性剤としては、ポリオキシアルキレンソルビタン脂肪酸エステル類、ポリオキシアルキレンソルビット脂肪酸エステル類、ポリオキシアルキレングリセリン脂肪酸エステル類、ポリオキシアルキレン脂肪酸エステル類、ポリオキシアルキレンアルキルエーテル類、ポリオキシアルキレンアルキルフェニルエーテル類、ポリオキシアルキレン（硬化）ヒマシ油類、ショ糖脂肪酸エステル類、ポリグリセリンアルキルエーテル類、ポリグリセリン脂肪酸エステル類、脂肪酸アルカノールアミド、アルキルグリコシド類等が挙げられる。このうち、成分（Ａ）以外のポリオキシアルキレンアルキルエーテル類、アルキルグリコシド類、ポリオキシアルキレン脂肪酸（炭素数８〜２０が好ましい。）エステル、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレン硬化ヒマシ油、脂肪酸アルカノールアミドが好ましい。成分（Ａ）以外のポリオキシアルキレンアルキルエーテル類としては、成分（Ａ）以外のポリオキシエチレンアルキルエーテル、ポリオキシプロピレンアルキルエーテル、ポリオキシエチレン・ポリオキシプロピレンアルキルエーテルが好ましい。アルキルグリコシド類としては、アルキル基の炭素数８〜１４で、糖（グルコース）の縮合度１〜２のものが好ましい。脂肪酸アルカノールアミドとしては、炭素数８〜１８、特に炭素数１０〜１６のアシル基を有するものが好ましく、またモノアルカノールアミド、ジアルカノールアミドのいずれでもよいが炭素数２〜３のヒドロキシアルキル基を有するものが好ましい。脂肪酸アルカノールアミドの具体例としては、オレイン酸ジエタノールアミド、パーム核油脂肪酸ジエタノールアミド、ヤシ油脂肪酸ジエタノールアミド、ラウリン酸ジエタノールアミド、ポリオキシエチレンヤシ油脂肪酸モノエタノールアミド、ヤシ油脂肪酸モノエタノールアミド、ラウリン酸モノイソプロパノールアミド、ラウリン酸モノエタノールアミド、パーム核油脂肪酸メチルエタノールアミド、ヤシ油脂肪酸メチルエタノールアミド等が挙げられる。 Nonionic surfactants include polyoxyalkylene sorbitan fatty acid esters, polyoxyalkylene sorbite fatty acid esters, polyoxyalkylene glycerin fatty acid esters, polyoxyalkylene fatty acid esters, polyoxyalkylene alkyl ethers, polyoxyalkylene alkyl. Examples include phenyl ethers, polyoxyalkylene (cured) castor oils, sucrose fatty acid esters, polyglycerin alkyl ethers, polyglycerin fatty acid esters, fatty acid alkanolamides, alkyl glycosides, and the like. Among these, polyoxyalkylene alkyl ethers other than the component (A), alkyl glycosides, polyoxyalkylene fatty acid (preferably having 8 to 20 carbon atoms) ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, Fatty acid alkanolamides are preferred. As the polyoxyalkylene alkyl ethers other than the component (A), polyoxyethylene alkyl ethers, polyoxypropylene alkyl ethers, and polyoxyethylene / polyoxypropylene alkyl ethers other than the component (A) are preferable. As the alkyl glycosides, those having an alkyl group having 8 to 14 carbon atoms and a sugar (glucose) condensation degree of 1 to 2 are preferable. As the fatty acid alkanolamide, those having an acyl group having 8 to 18 carbon atoms, particularly 10 to 16 carbon atoms are preferable, and either a monoalkanolamide or a dialkanolamide may be used, but a hydroxyalkyl group having 2 to 3 carbon atoms may be used. What has is preferable. Specific examples of fatty acid alkanolamides include oleic acid diethanolamide, palm kernel oil fatty acid diethanolamide, coconut oil fatty acid diethanolamide, lauric acid diethanolamide, polyoxyethylene coconut oil fatty acid monoethanolamide, coconut oil fatty acid monoethanolamide, laurin Examples include acid monoisopropanolamide, lauric acid monoethanolamide, palm kernel oil fatty acid methylethanolamide, and coconut oil fatty acid methylethanolamide.
両性界面活性剤としては、ベタイン系界面活性剤及びアミンオキサイド型界面活性剤等が挙げられる。このうち、イミダゾリン系ベタイン、アルキルジメチルアミノ酢酸ベタイン、脂肪酸アミドプロピルベタイン、スルホベタイン等のベタイン系界面活性剤及びアルキルジメチルアミンオキサイド等のアミンオキサイド型界面活性剤がより好ましく、アルキルカルボキシメチルヒドロキシエチルイミダゾリウムベタイン、脂肪酸アミドプロピルベタイン、アルキルヒドロキシスルホベタイン、アルキルスルホベタイン、脂肪酸アミドプロピルヒドロキシスルホベタイン及び脂肪酸アミドプロピルスルホベタイン等のスルホベタイン並びにアルキルジメチルアミンオキサイドが更に好ましい。アルキルジメチルアミンオキサイドは、炭素数８〜１８、特に炭素数１０〜１６のアルキル基を有するものが好ましく、特にラウリルジメチルアミンオキサイド及びミリスチルジメチルアミンオキサイドが好ましい。 Examples of amphoteric surfactants include betaine surfactants and amine oxide surfactants. Of these, betaine surfactants such as imidazoline betaines, alkyldimethylaminoacetic acid betaines, fatty acid amidopropyl betaines, and sulfobetaines, and amine oxide surfactants such as alkyldimethylamine oxides are more preferred, and alkylcarboxymethylhydroxyethylimidazo More preferred are sulfobetaines such as lithium betaine, fatty acid amidopropyl betaine, alkylhydroxysulfobetaine, alkylsulfobetaine, fatty acid amidopropylhydroxysulfobetaine and fatty acid amidopropylsulfobetaine, and alkyldimethylamine oxide. The alkyldimethylamine oxide preferably has an alkyl group having 8 to 18 carbon atoms, particularly 10 to 16 carbon atoms, and lauryldimethylamine oxide and myristyldimethylamine oxide are particularly preferable.
界面活性剤は単独で、あるいはより乳化・分散・可溶化性能を高めるために２種以上を組み合わせて用いることができる。 Surfactants can be used alone or in combination of two or more in order to enhance the emulsification / dispersion / solubilization performance.
成分（Ｃ）として界面活性剤を含有する場合、本発明の皮膚外用剤における成分（Ａ）と成分（Ｃ）の界面活性剤の重量比率（成分（Ａ）の含有量）／（成分（Ｃ）の界面活性剤の含有量）は、毒素産生抑制効果の点から２以下が好ましく、２／１〜１／１００がより好ましく、２／１〜１／５０がより好ましく、２／１〜１／２０が更に好ましく、１／１〜１／１０がより更に好ましい。 When a surfactant is contained as component (C), the weight ratio of component (A) to component (C) surfactant in the external preparation for skin of the present invention (content of component (A)) / (component (C ) Is preferably 2 or less, more preferably 2/1 to 1/100, more preferably 2/1 to 1/50, and 2/1 to 1 in view of the toxin production inhibitory effect. / 20 is more preferable, and 1/1 to 1/10 is still more preferable.
また、本発明の皮膚外用剤における成分（Ｃ）の界面活性剤の含有量は、乳化・分散・可溶化性能の観点から０．０００５〜５０重量％が好ましく、より好ましくは０．００２５〜３０重量％、更に０．００５〜１５重量％が好ましい。さらに０．０１〜１０重量％が好ましく、０．１〜５重量％がより好ましい。 In addition, the content of the component (C) surfactant in the external preparation for skin of the present invention is preferably 0.0005 to 50% by weight, more preferably 0.0025 to 30% from the viewpoint of emulsification / dispersion / solubilization performance. % By weight, more preferably 0.005 to 15% by weight. Furthermore, 0.01 to 10 weight% is preferable and 0.1 to 5 weight% is more preferable.
また、成分（Ｃ）の溶剤としては、炭素数４〜７の１価アルコール、グリコール等のポリオール、ジエチレングリコールモノメチルエーテル等のグリコールエーテル、油脂、ロウ類、炭化水素油等が挙げられ、炭素数４〜７の１価アルコール、グリコール等のポリオール、中でも炭素数２〜４のポリオールが好ましい。１価アルコールとしてはｎ−ブタノール等が挙げられる。ポリオールとしてはエチレングリコール、プロピレングリコール、１，３−ブチレングリコール、２，３−ブチレングリコール、ヘキシレングリコール、ジプロピレングリコール、ポリエチレングリコール等のグリコール、グリセリン、ジグリセリン等が挙げられる。グリコールエーテルとしては、ジエチレングリコールモノメチルエーテル等が挙げられる。油脂、ロウ類、炭化水素油としては、ワセリン、スクワラン、パラフィン、コレステロール、動植物性のトリグリセライド等が挙げられる。好ましくは、プロピレングリコール、ポリエチレングリコール（重量平均分子量１００〜１０００）である。 Examples of the solvent for component (C) include monohydric alcohols having 4 to 7 carbon atoms, polyols such as glycol, glycol ethers such as diethylene glycol monomethyl ether, fats and oils, waxes, hydrocarbon oils, and the like. Polyols such as ˜7 monohydric alcohols, glycols, etc., and especially those having 2 to 4 carbon atoms are preferred. Examples of monohydric alcohols include n-butanol. Examples of the polyol include glycols such as ethylene glycol, propylene glycol, 1,3-butylene glycol, 2,3-butylene glycol, hexylene glycol, dipropylene glycol, and polyethylene glycol, glycerin, and diglycerin. Examples of the glycol ether include diethylene glycol monomethyl ether. Examples of fats and oils, waxes, and hydrocarbon oils include petrolatum, squalane, paraffin, cholesterol, and animal and plant triglycerides. Preferably, they are propylene glycol and polyethylene glycol (weight average molecular weight 100-1000).
これらは、単独あるいは２種以上を併用して用いることができ、上記の界面活性剤と併用して用いることができる。また、本発明の皮膚外用剤における成分（Ｃ）の溶剤の含有量は、０．０５〜５０重量％であることが好ましく、より好ましくは０．１〜２０重量％、更に０．５〜１０重量％が好ましい。 These can be used alone or in combination of two or more, and can be used in combination with the above surfactant. Moreover, it is preferable that content of the solvent of the component (C) in the skin external preparation of this invention is 0.05-50 weight%, More preferably, it is 0.1-20 weight%, Furthermore, 0.5-10 % By weight is preferred.
本発明の皮膚外用剤は、上記成分以外に、化粧料、皮膚外用剤に用いられる任意の成分を、本発明の効果を損なわない範囲で用いることができる。例えば、高級脂肪酸、合成エステル類、シリコーン、金属封鎖剤、水溶性高分子、増粘剤、パウダー成分、着色剤、着香剤、収斂剤、抗炎症剤、保湿剤、ｐＨ調整剤、殺菌剤、植物エキス類などが挙げられる。 The skin external preparation of this invention can use the arbitrary components used for cosmetics and a skin external preparation other than the said component in the range which does not impair the effect of this invention. For example, higher fatty acids, synthetic esters, silicone, metal sequestering agents, water-soluble polymers, thickeners, powder components, coloring agents, flavoring agents, astringents, anti-inflammatory agents, moisturizers, pH adjusters, bactericides And plant extracts.
本発明の皮膚外用剤の製品形態としては、液状、ゲル状、固体状、クリーム状、水−油の２相分離系又はエアゾール等が挙げられる。使用方法としては直接塗布、噴霧あるいは、予め、布、不織布、紙などに含浸させておいて塗布しても良い。本発明の皮膚外用剤が洗浄剤である場合には、洗浄後、濯ぐことにより用いるのが好ましい。また、本発明の皮膚外用剤が皮膚表面上に長時間残存するようなリーブオンの形態であることがより好ましい。本発明の皮膚外用剤は、人体のみならず、ペット等の動物の皮膚にも用いることができる。 Examples of the product form of the external preparation for skin of the present invention include liquid, gel, solid, cream, water-oil two-phase separation system or aerosol. As a method of use, direct application, spraying, or impregnation into cloth, nonwoven fabric, paper or the like may be applied. When the external preparation for skin of the present invention is a cleaning agent, it is preferably used by rinsing after cleaning. Moreover, it is more preferable that the external preparation for skin of the present invention is in the form of a leave-on that remains on the skin surface for a long time. The external preparation for skin of the present invention can be used not only on the human body but also on the skin of animals such as pets.
本発明の皮膚外用剤は、特に制限されるものではないが、手指の清浄や頭皮のケアに用いることができる。 The external preparation for skin of the present invention is not particularly limited, but can be used for finger cleaning and scalp care.
本発明の皮膚外用剤のｐＨは、毒素産生抑制効果と皮膚刺激性の観点から、２０℃で２〜１１が好ましく、より好ましくは３〜１０、更に好ましくは４〜９であり、６〜８が特に好ましい。 From the viewpoint of the toxin production inhibitory effect and skin irritation, the pH of the external preparation for skin of the present invention is preferably 2-11 at 20 ° C., more preferably 3-10, still more preferably 4-9, and 6-8. Is particularly preferred.
本発明の皮膚外用剤は、皮膚上の微生物の毒素産生抑制に用いる皮膚外用剤である。人の皮膚表面には生体防御としての役割を果たしている皮膚常在菌（表皮ブドウ球菌やコリネバクテリウム属など）や病原微生物である黄色ブドウ球菌が生息している。皮膚表面に生息する病原微生物が増殖すると毒素を産生することが知られている。この病原微生物が産生する毒素により様々な皮膚トラブルが引き起こされる。例えば、病原微生物である黄色ブドウ球菌が産生するα−トキシンやδ−トキシン、表皮剥離毒素などにより、頭皮のかゆみあるいは創傷治癒遅延やアトピー性皮膚炎、皮膚掻痒症、接触皮膚炎の悪化などの様々なトラブルが引き起こされる。本発明の皮膚外用剤の毒素産生抑制能については、成分（Ｂ）の殺菌効果を取り除いて確認することができる。例えば、後述の実施例１に示した通り、本発明の皮膚外用剤を希釈して確認しても良いし、成分（Ｂ）を揮発させて確認しても良い。すなわち、本発明の皮膚外用剤の毒素産生抑制能は、本発明の皮膚外用剤を希釈して、或いは、本発明の皮膚外用剤の成分（Ｂ）を揮発させた後、黄色ブドウ球菌に対して作用させた時に産生されるδ−トキシン量（Ｖ１）が、皮膚外用剤を作用させない時に産生されるδ−トキシン量（Ｖ０）と比較して減少する程度〔即ち、（Ｖ０−Ｖ１）の大小〕により確認することができる。 The external preparation for skin of the present invention is an external preparation for skin used for suppressing the production of toxins by microorganisms on the skin. The human skin surface is inhabited by resident skin bacteria (such as Staphylococcus epidermidis and Corynebacterium) that play a role as a biological defense and Staphylococcus aureus that is a pathogenic microorganism. It is known that when pathogenic microorganisms that inhabit the skin surface proliferate, toxins are produced. Toxins produced by this pathogenic microorganism cause various skin problems. For example, alpha-toxin, delta-toxin produced by the pathogenic microorganism Staphylococcus aureus, epidermal exfoliation toxin, etc. may cause itching of the scalp or delayed wound healing, atopic dermatitis, dermatitis, contact dermatitis, etc. Various troubles are caused. The ability to suppress toxin production of the external preparation for skin of the present invention can be confirmed by removing the bactericidal effect of component (B). For example, as shown in Example 1 described later, the skin external preparation of the present invention may be diluted and confirmed, or the component (B) may be volatilized for confirmation. That is, the ability to suppress toxin production of the external preparation for skin of the present invention is obtained by diluting the external preparation for skin of the present invention or volatilizing the component (B) of the external preparation for skin of the present invention, The amount of δ-toxin (V1) produced when allowed to act is reduced to a level that is less than the amount of δ-toxin produced when not applied to the skin external preparation (V0) [ie (V0-V1) It can be confirmed by [large or small].
成分（Ａ）を０．００１〜５重量％及び成分（Ｂ）を２５〜８５重量％含有する皮膚外用剤により、皮膚上の微生物由来毒素の産生を抑制する方法が提供される。本発明の皮膚外用剤は、皮膚上での微生物の増殖を妨げることなく、微生物による皮膚表面での様々なトラブルを抑制することができる。本発明の成分（Ｂ）には一時的な殺菌効果があるが、成分（Ａ）と併用することで、日単位でみた場合に微生物の増殖を妨げない皮膚外用剤を得ることができる。すなわち、本発明の皮膚外用剤を皮膚に適用した直後は、成分（Ｂ）の作用により皮膚表面に存在する微生物が一時的に殺菌されることはあっても、生き残った微生物または皮膚内部に存在する微生物がすぐに増殖してくることや、適用後すぐに成分（Ｂ）が蒸発して殺菌性が失われるため、その後は増殖に影響を及ぼさない。その結果、日単位での微生物の増殖を妨げることなく、微生物由来の毒素産生を著しく抑制することができる。 A method for suppressing the production of microorganism-derived toxins on the skin is provided by an external preparation for skin containing 0.001 to 5% by weight of component (A) and 25 to 85% by weight of component (B). The external preparation for skin of the present invention can suppress various troubles caused by microorganisms on the skin surface without hindering the growth of microorganisms on the skin. The component (B) of the present invention has a temporary bactericidal effect, but when used in combination with the component (A), an external skin preparation that does not interfere with the growth of microorganisms when viewed on a daily basis can be obtained. That is, immediately after the skin external preparation of the present invention is applied to the skin, the microorganisms present on the skin surface may be temporarily sterilized by the action of the component (B), but are still present in the surviving microorganisms or in the skin. Since the microorganisms to be grown immediately grow or the component (B) evaporates immediately after application and the bactericidal property is lost, the growth is not affected thereafter. As a result, the production of microorganism-derived toxins can be remarkably suppressed without hindering the growth of microorganisms on a daily basis.
なお、本発明の皮膚外用剤は日単位の微生物の増殖を妨げないものであるが、長期的な微生物の増殖抑制を評価する場合は、成分（Ｂ）の影響を考慮しない条件を採用して、成分（Ａ）による微生物の増殖抑制効果を評価することができる。例えば、後述の実施例のようなin vitro試験では、皮膚に適用するin vivo試験とは異なり、エタノールや１−プロパノール、２−プロパノールなどの成分（Ｂ）を含有する皮膚外用剤を使用した場合、培養開始の段階で黄色ブドウ球菌が殺菌されてしまい、毒素産生抑制能評価に影響を及ぼす可能性が考えられる。そのため、成分（Ｂ）の一時的な殺菌効果の影響を排除して微生物の増殖抑制を評価することが適切である。すなわち、本発明において、長期的な微生物の増殖抑制を評価する場合は、成分（Ａ）のみを適用する、本発明の皮膚外用剤を希釈する、成分（Ｂ）を揮発させる、等により、実質的に成分（Ｂ）の影響が無視できる条件で、成分（Ａ）を微生物に適用し、所定の条件にて微生物を培養後、静止期（stationary phase：細菌の分裂率と死滅率が平衡に達して生菌数が一定となる、つまり最も菌濃度が高い時期）における菌数Ｎが、コントロールの菌数Ｎ０と比べると、菌数の比が０．１＜Ｎ／Ｎ０＜１０となる場合を、長期的（日単位の増殖期間）に「微生物の増殖を妨げない」とする。他方、この長期的な評価において「微生物の増殖を妨げる」とは、Ｎ／Ｎ０≦０．１となることである。この菌数は、後述の実施例のように、便宜的に培地中の微生物に対して試験した結果であってもよい。 In addition, although the skin external preparation of this invention is a thing which does not prevent the proliferation of microorganisms of a day unit, when evaluating long-term growth suppression of microorganisms, the conditions which do not consider the influence of a component (B) are employ | adopted. The effect of inhibiting the growth of microorganisms by component (A) can be evaluated. For example, in the in vitro test as in the examples described later, unlike the in vivo test applied to the skin, when an external skin preparation containing a component (B) such as ethanol, 1-propanol, 2-propanol is used. There is a possibility that Staphylococcus aureus is sterilized at the start of the culture and affects the evaluation of the ability to inhibit toxin production. Therefore, it is appropriate to evaluate the growth inhibition of microorganisms by eliminating the influence of the temporary bactericidal effect of component (B). That is, in the present invention, when evaluating long-term suppression of the growth of microorganisms, only the component (A) is applied, the skin external preparation of the present invention is diluted, the component (B) is volatilized, etc. The component (A) is applied to the microorganism under conditions where the influence of the component (B) can be ignored, and after culturing the microorganism under the predetermined condition, the stationary phase (bacteria division rate and death rate are balanced) When the number of bacteria N reaches a constant number of viable bacteria, that is, when the concentration of bacteria is the highest), the ratio of the number of bacteria is 0.1 <N / N0 <10 when compared to the number N0 of the control Is “not hindering the growth of microorganisms” in the long term (daily growth period). On the other hand, in this long-term evaluation, “preventing the growth of microorganisms” means that N / N0 ≦ 0.1. This number of bacteria may be the result of testing against microorganisms in the medium for convenience, as in the examples described below.
また、本発明の皮膚外用剤は、黄色ブドウ球菌等のグラム陽性菌に対する増殖抑制効果を持たないものが好ましい。なお、ここで、「増殖抑制効果を持たない」とは、１０8cfu/mL以下の濃度の菌液に対して対象となるサンプルの皮膚外用剤を用いた場合に、Tryptic Soy Broth No.2培地にて３７℃の条件で培養した場合、静止期（stationary phase）において、グラム陽性菌の菌数が１０9cfu/mLに達することをいう。 In addition, the external preparation for skin of the present invention preferably has no growth inhibitory effect against Gram-positive bacteria such as Staphylococcus aureus. Here, “having no growth-inhibiting effect” means Tryptic Soy Broth No. 2 when the target skin external preparation is used against a bacterial solution having a concentration of 10 8 cfu / mL or less. When cultured in a medium at 37 ° C., the number of Gram-positive bacteria reaches 10 9 cfu / mL in the stationary phase.
以下の実施例で用いた成分を示す。 The components used in the following examples are shown.
＜成分（Ａ）＞
（Ａ−１） １−ノナノール
（Ａ−２） １−デカノール
（Ａ−３） １−ウンデカノール
（Ａ−４） トランス−２−ドデセン−１−オール
（Ａ−５） １−ドデカノール
（Ａ−６） １−トリデカノール
（Ａ−７） １−テトラデカノール
（Ａ−８） １−ペンタデカノール
（Ａ−９） １−ヘキサデカノール
（Ａ−１０） ２−ヘキサデカノール
（Ａ−１１） １−ヘプタデカノール
（Ａ−１２） １−オクタデカノール
（Ａ−１３） ジエチレングリコールモノデシルエーテル
（Ａ−１４） トリエチレングリコールモノデシルエーテル
（Ａ−１５） テトラエチレングリコールモノデシルエーテル
（Ａ−１６） ペンタエチレングリコールモノデシルエーテル
（Ａ−１７） オクタエチレングリコールモノデシルエーテル
（Ａ−１８） ジエチレングリコールモノドデシルエーテル
（Ａ−１９） トリエチレングリコールモノドデシルエーテル
（Ａ−２０） テトラエチレングリコールモノドデシルエーテル
（Ａ−２１） ペンタエチレングリコールモノドデシルエーテル
（Ａ−２２） ヘキサエチレングリコールモノドデシルエーテル
（Ａ−２３） ヘプタエチレングリコールモノドデシルエーテル
（Ａ−２４） オクタエチレングリコールモノドデシルエーテル
（Ａ−２５） ドデカエチレングリコールモノドデシルエーテル
（Ａ−２６） トリエチレングリコールモノテトラデシルエーテル
（Ａ−２７） テトラエチレングリコールモノテトラデシルエーテル
（Ａ−２８） ペンタエチレングリコールモノテトラデシルエーテル
（Ａ−２９） ヘキサエチレングリコールモノテトラデシルエーテル
<Component (A)>
(A-1) 1-nonanol (A-2) 1-decanol (A-3) 1-undecanol (A-4) trans-2-dodecen-1-ol (A-5) 1-dodecanol (A-6) 1-tridecanol (A-7) 1-tetradecanol (A-8) 1-pentadecanol (A-9) 1-hexadecanol (A-10) 2-hexadecanol (A-11) 1 -Heptadecanol (A-12) 1-octadecanol (A-13) Diethylene glycol monodecyl ether (A-14) Triethylene glycol monodecyl ether (A-15) Tetraethylene glycol monodecyl ether (A-16) Pentaethylene glycol monodecyl ether (A-17) Octaethylene glycol monodecyl ether (A-18) Diethylene glycol Monododecyl ether (A-19) Triethylene glycol monododecyl ether (A-20) Tetraethylene glycol monododecyl ether (A-21) Pentaethylene glycol monododecyl ether (A-22) Hexaethylene glycol monododecyl ether (A- 23) Heptaethylene glycol monododecyl ether (A-24) Octaethylene glycol monododecyl ether (A-25) Dodecaethylene glycol monododecyl ether (A-26) Triethylene glycol monotetradecyl ether (A-27) Tetraethylene glycol Monotetradecyl ether (A-28) Pentaethylene glycol monotetradecyl ether (A-29) Hexaethylene glycol monotetradecyl ether
＜成分（Ａ’）（比較化合物）＞
（Ａ’−１） １−ペンタノール
（Ａ’−２） １−オクタノール
<Component (A ') (Comparative Compound)>
(A′-1) 1-pentanol (A′-2) 1-octanol
＜成分（Ｂ）＞
（Ｂ−１） エタノール
（Ｂ−２） １−プロパノール
（Ｂ−３） ２−プロパノール（イソプロパノール）
<Component (B)>
(B-1) Ethanol (B-2) 1-propanol (B-3) 2-propanol (isopropanol)
＜成分（Ｃ）＞
（Ｃ−１） ポリオキシエチレン（エチレンオキシド平均付加モル数４．５）ドデシルエーテル酢酸ナトリウム
（Ｃ−２） モノドデカン酸ポリエチレングリコール（エチレンオキシド平均付加モル数１２）
（Ｃ−３） ドデシルグルコシド
（Ｃ−４） プロピレングリコール
<Ingredient (C)>
(C-1) Polyoxyethylene (ethylene oxide average addition mole number 4.5) sodium dodecyl ether acetate (C-2) Monododecanoic acid polyethylene glycol (ethylene oxide average addition mole number 12)
(C-3) Dodecyl glucoside (C-4) Propylene glycol
実施例１
成分（Ａ）又は成分（Ａ’）、成分（Ｂ）、成分（Ｃ）及びイオン交換水を表１〜３に示す含有量で配合し、本発明品、比較品の皮膚外用剤を調製した。皮膚外用剤のｐＨ（２０℃）は、６．５〜７．０の範囲とした。
Example 1
Component (A) or component (A ′), component (B), component (C), and ion-exchanged water were blended in the contents shown in Tables 1 to 3 to prepare the skin external preparations of the present invention and comparative products. . The pH (20 ° C.) of the external preparation for skin was in the range of 6.5 to 7.0.
本発明品及び比較品を、Tryptic Soy Broth No.2培地〔TSB No.2培地、シグマアルドリッチジャパン（株）〕を用いて１重量％に希釈し、これを培養フラスコ〔ベクトン・ディッキンソン（株）製〕に14.85mL入れた（なお、本試験では、成分（Ｂ）の一時的な殺菌効果の影響を排除するために本発明品及び比較品を１重量％に希釈して試験を行った。）。次に、黄色ブドウ球菌（staphylococcus aureus NCTC8325株）をTryptic Soy Broth No.2培地〔TSB No.2培地、シグマアルドリッチジャパン（株）〕中で、３７℃、１８時間振とう培養（前培養）した後、生理食塩水〔大塚製薬（株）製〕を用いて105cfu/mLの菌液を調製した。そして、培養フラスコに調製した菌液を150μL添加した後、３７℃の条件で振とう培養を行い、３６時間培養後の静止期（stationary phase）における菌数及びδ−トキシン量を定量した。 The product of the present invention and the comparative product are diluted to 1% by weight using Tryptic Soy Broth No. 2 medium [TSB No. 2 medium, Sigma Aldrich Japan Co., Ltd.], and this is diluted with a culture flask [Becton Dickinson Co., Ltd.] (In this test, in order to eliminate the influence of the temporary bactericidal effect of the component (B), the product of the present invention and the comparative product were diluted to 1% by weight, and the test was conducted. ). Next, S. aureus (staphylococcus aureus NCTC8325 strain) was shaken (pre-cultured) at 37 ° C. for 18 hours in Tryptic Soy Broth No. 2 medium [TSB No. 2 medium, Sigma-Aldrich Japan Co., Ltd.]. Thereafter, a 10 5 cfu / mL bacterial solution was prepared using physiological saline (manufactured by Otsuka Pharmaceutical Co., Ltd.). Then, 150 μL of the prepared bacterial solution was added to the culture flask, followed by shaking culture at 37 ° C., and the number of bacteria and the amount of δ-toxin in the stationary phase after 36 hours of culture were quantified.
菌数の定量方法としては、寒天平板希釈法に従い、３６時間培養の培養液または生理食塩水で10倍、102倍、103倍、104倍、105倍、106倍、107倍に希釈した培養液をSMA培地〔日本製薬（株）〕に100μL撒いて24時間静置培養し、培地上に形成したコロニーをカウントした。結果を表１〜３に示す。 As a method for quantifying the number of bacteria, according to the agar plate dilution method, 10 times, 10 2 times, 10 3 times, 10 4 times, 10 5 times, 10 6 times, 10 7 times with a culture solution or physiological saline cultured for 36 hours. 100 μL of the diluted culture solution was spread on SMA medium [Nippon Pharmaceutical Co., Ltd.] and allowed to stand for 24 hours, and colonies formed on the medium were counted. The results are shown in Tables 1-3.
また、δ−トキシン量の定量方法としては、遠心分離機〔日立（株）〕を使用して、菌数定量試験に使用しなかった残りの培養液を菌と上清に分け、さらにcellulose acetate 0.2μｍフィルター〔アドバンテック（株）〕を用いて上清から菌を除外した。そして逆相-HPLCを用いてこの上清中に含まれるδ−トキシン量つまり、黄色ブドウ球菌が産生したδ−トキシン量を定量した。δ−トキシン量の定量は、Michael Ottoらの文献（Michael Otto , Friedrich. 2000. BioTechniques 28: 1088-1096.）を参考にして測定を行った。また、検量線は人工的に合成したδ−トキシン（東レリサーチセンター（株）製）を使用して作成した。結果を表１〜３に示す。 In addition, as a method for quantifying the amount of δ-toxin, a centrifuge [Hitachi Co., Ltd.] was used, and the remaining culture solution that was not used in the bacterial count quantification test was divided into bacteria and supernatant, and further cellulose acetate Bacteria were excluded from the supernatant using a 0.2 μm filter [Advantech Co., Ltd.]. Then, the amount of δ-toxin contained in the supernatant, that is, the amount of δ-toxin produced by Staphylococcus aureus was quantified using reverse phase-HPLC. The amount of δ-toxin was measured with reference to Michael Otto et al. (Michael Otto, Friedrich. 2000. BioTechniques 28: 1088-1096). The calibration curve was prepared using artificially synthesized δ-toxin (manufactured by Toray Research Center Co., Ltd.). The results are shown in Tables 1-3.
尚、表１〜３において、皮膚外用剤の希釈物を作用させない時に産生されるδ−トキシン量（Ｖ０）は、比較品を作用させた場合のδ−トキシン産生量である。これに対して、本発明品の希釈物を作用させた場合に産生されるδ−トキシン量（Ｖ１）は表１、表２に示されたδ−トキシン産生量である。 In Tables 1 to 3, the amount of δ-toxin (V0) produced when no dilution of the external preparation for skin is allowed to act is the amount of δ-toxin produced when a comparative product is allowed to act. On the other hand, the amount of δ-toxin produced when the diluted product of the present invention is allowed to act (V1) is the amount of δ-toxin produced as shown in Tables 1 and 2.
すべての系で黄色ブドウ球菌は１０9cfu/mL以上まで増殖する傾向が確認されたが、成分（Ａ）及び成分（Ｂ）を含有する本発明品１−１〜１−３３ではδ−トキシンの産生が抑制されていた。また本発明品１−８と１−９の比較または、本発明品１−２３と１−２４の比較から、成分（Ｃ）の添加により、さらにδ−トキシン産生抑制能が向上することが明らかになった。一方、成分（Ａ’）及び成分（Ｂ）を含有する比較品１−１〜１−１３ではδ−トキシンの産生は抑制されない。また、成分（Ａ）のみを含有する比較品１−１４〜１−１７では、成分（Ａ）が十分に溶解していないため、δ−トキシンの産生は抑制されない。よって、成分（Ａ）と成分（Ｂ）の併用によりδ−トキシンを抑制できることと、この系に成分（Ｃ）をさらに加えることによりδ−トキシン産生抑制能が向上することが明らかになった。この結果から、本発明の皮膚外用剤は、皮膚上での黄色ブドウ球菌の増殖を妨げずに黄色ブドウ球菌が産生するδ−トキシンを抑制できるものと推察される。 In all systems, Staphylococcus aureus tended to grow to 10 9 cfu / mL or more. However, in the products of the present invention 1-1 to 1-33 containing component (A) and component (B), δ-toxin Production was suppressed. In addition, it is clear from the comparison between the inventive products 1-8 and 1-9 or the inventive products 1-23 and 1-24 that the addition of component (C) further improves the ability to suppress δ-toxin production. Became. On the other hand, in the comparative products 1-1 to 1-13 containing the component (A ′) and the component (B), the production of δ-toxin is not suppressed. Moreover, in the comparative products 1-14 to 1-17 containing only the component (A), since the component (A) is not sufficiently dissolved, the production of δ-toxin is not suppressed. Therefore, it became clear that δ-toxin can be suppressed by the combined use of component (A) and component (B), and that the ability to suppress δ-toxin production is improved by further adding component (C) to this system. From this result, it is inferred that the external preparation for skin of the present invention can suppress δ-toxin produced by S. aureus without hindering the growth of S. aureus on the skin.
実施例２
常法により表４の化粧料を製造した。試験は本発明品、比較品各群について頭皮のかゆみの自覚症状を持つ各１０名に対して行った。試験品使用直前に頭皮のかゆみの状態を下記の基準で自己申告させた。洗髪後に試験品を１日に１回３ｍLを頭皮全体に均一に塗布し、７日間使用させた後、試験開始日から８日後に再度、頭皮のかゆみの状態を下記の基準で自己申告させた。尚、試験品使用開始１週間前より試験終了までの間、かゆみ抑制剤、殺菌剤含有シャンプー及びリンス、コンディショナー、整髪料等の使用は禁止し、全員が殺菌剤未配合の同じシャンプーのみを使用した。１０名の評点の平均で評価した。結果を表４に示す。
Example 2
The cosmetics shown in Table 4 were produced by a conventional method. The test was carried out on each of 10 persons with subjective symptoms of scalp itch in each group of the present invention product and comparative product. Immediately before using the test product, the condition of scalp itching was self-reported according to the following criteria. After washing the hair, apply 3 mL of the test product once a day to the entire scalp evenly and use it for 7 days. After 8 days from the start of the test, the condition of scalp itching was self-reported based on the following criteria. . It should be noted that the use of itch suppressants, bactericide-containing shampoos and rinses, conditioners, hair styling, etc. is prohibited from the week before the test product is used until the end of the test, and all use only the same shampoo that does not contain bactericides. did. Evaluation was based on an average of 10 people. The results are shown in Table 4.
かゆみの基準
１， かゆみを全く感じない
２， かゆみを少し感じる
３， かゆみを感じる
４， かゆみを強く感じる
Itchy standard 1, I don't feel itchy at all 2, I feel a little itchy 3, I feel itchy 4, I feel itchy
（処方例１）
成分（Ａ）としてトリエチレングリコールモノドデシルエーテルを０．０１質量％、成分（Ｂ）として９５度エタノールを８０質量％、成分（Ｃ）としてグリセリンを０．１質量％、精製水を１９．８９質量％含有する手指用アルコール製剤。
(Prescription Example 1)
As component (A), 0.01% by mass of triethylene glycol monododecyl ether, as component (B), 80% by mass of 95 degree ethanol, as component (C), 0.1% by mass of glycerin, and 19.89 of purified water. Alcohol preparation for fingers containing mass%.
（処方例２）
成分（Ａ）としてトリエチレングリコールモノドデシルエーテルを０．０１質量％、成分（Ｂ）として９５度エタノールを２５質量％、成分（Ｃ）としてポリオキシエチレン硬化ヒマシ油（ＥＯ６０モル）を０．１質量％、成分（Ｃ）としてグリセリンを０．１質量％、パラオキシ安息香酸メチルを０．１質量％、香料を０．０５％、精製水を７４．６４質量％含有する頭皮ケア剤。
(Prescription example 2)
0.01% by mass of triethylene glycol monododecyl ether as component (A), 25% by mass of 95 ° ethanol as component (B), 0.1% of polyoxyethylene hydrogenated castor oil (EO 60 mol) as component (C) A scalp care agent containing 0.1% by mass of glycerin as component (C), 0.1% by mass of methyl paraoxybenzoate, 0.05% of fragrance, and 74.64% by mass of purified water.
Claims (6)
Ｒ1−ＯＨ （ａ１）
（式中、Ｒ1は炭素数９〜１８の炭化水素基を示す。）
Ｒ2−Ｏ−（ＥＯ）n−Ｈ （ａ２）
（式中、Ｒ2は炭素数８〜１８の炭化水素基を示し、ＥＯはエチレンオキシ基を示し、ｎは１〜１５の整数を示す。） 0.001 to 5% by weight of one or more compounds (A) selected from the compound represented by the following general formula (a1) and the compound represented by the general formula (a2), and having 2 to 3 carbon atoms A topical skin preparation for use in inhibiting staphylococcus aureus δ-toxin production, containing 25 to 85% by weight of monohydric alcohol (B).
R 1 —OH (a1)
(In the formula, R 1 represents a hydrocarbon group having 9 to 18 carbon atoms.)
R 2 —O— (EO) n —H (a2)
(In the formula, R 2 represents a hydrocarbon group having 8 to 18 carbon atoms, EO represents an ethyleneoxy group, and n represents an integer of 1 to 15).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011210419A JP5937321B2 (en) | 2011-09-27 | 2011-09-27 | Skin preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011210419A JP5937321B2 (en) | 2011-09-27 | 2011-09-27 | Skin preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013071895A JP2013071895A (en) | 2013-04-22 |
| JP5937321B2 true JP5937321B2 (en) | 2016-06-22 |
Family
ID=48476666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011210419A Active JP5937321B2 (en) | 2011-09-27 | 2011-09-27 | Skin preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5937321B2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5735388B2 (en) * | 2011-09-27 | 2015-06-17 | 花王株式会社 | Microbial toxin production inhibitor |
| JP2017203021A (en) * | 2016-05-13 | 2017-11-16 | 株式会社アルボース | Sterilizing composition |
| JP7257155B2 (en) * | 2019-01-31 | 2023-04-13 | 花王株式会社 | skin antiseptic composition |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2728921C3 (en) * | 1977-06-27 | 1984-07-05 | Dragoco Gerberding & Co Gmbh, 3450 Holzminden | Use of farnesol as a bacteriostat in body deodorants |
| JP2656301B2 (en) * | 1988-04-22 | 1997-09-24 | 旭電化工業株式会社 | Hand sanitizer cleaning agent |
| JP2907640B2 (en) * | 1992-06-29 | 1999-06-21 | 高砂香料工業株式会社 | Skin external preparation for acne vulgaris |
| JP2937667B2 (en) * | 1992-11-19 | 1999-08-23 | 高砂香料工業株式会社 | Skin external preparation for acne vulgaris |
| JP5103041B2 (en) * | 2006-03-23 | 2012-12-19 | 花王株式会社 | Biofilm formation inhibitor composition |
| JP5162191B2 (en) * | 2007-09-25 | 2013-03-13 | 花王株式会社 | Topical skin preparation |
-
2011
- 2011-09-27 JP JP2011210419A patent/JP5937321B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013071895A (en) | 2013-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016022235B1 (en) | ANTIMICROBIAL DERMAL CONCENTRATE | |
| JP5162191B2 (en) | Topical skin preparation | |
| JP5140267B2 (en) | Liquid disinfectant cleaning composition | |
| JP5637987B2 (en) | Preservative composition | |
| JP2017025005A (en) | Antiseptic agent containing emblica officinalis | |
| CN106109259B (en) | A kind of shampoo shower cream preventing stink with perspiration | |
| KR102618673B1 (en) | Antibacterial and antiseptic composition | |
| JP5937321B2 (en) | Skin preparation | |
| JP2013256481A (en) | Antimicrobial agent and cosmetic | |
| JP6474963B2 (en) | Cleaning composition | |
| CN107854329B (en) | A kind of antibacterial moisturizing foam hand cleanser of easy wash type and preparation method thereof | |
| ES2898925T3 (en) | Propanediol monoacetate-mononitrate | |
| JP5735388B2 (en) | Microbial toxin production inhibitor | |
| ES2873839T3 (en) | Antimicrobial mixture containing 4- (3-ethoxy-4-hydroxyphenyl) butan-2-one and a diol, and cosmetic composition containing the same | |
| TWI645849B (en) | Use of coco polyether sulfate as antibacterial agent against P. acnes | |
| JP5013765B2 (en) | Antiseptic disinfectant, cosmetics, pharmaceuticals or foods containing the antiseptic disinfectant | |
| JP2007145748A (en) | Antiseptic sterilizer, cosmetic or medicine containing the antiseptic sterilizer, and method for antiseptic sterilization | |
| CN110831570B (en) | New use | |
| JP2013071894A (en) | Toxin production inhibitor for microorganism | |
| CN106619319B (en) | A kind of itching-relieving shower dew and preparation method thereof containing antibacterial peptide | |
| RU2813149C9 (en) | Antimicrobial compositions | |
| KR19980084521A (en) | Hair cosmetic composition having anti-dandruff effect | |
| CN100563439C (en) | Broad spectrum preservation blends | |
| JP7112706B2 (en) | ANTIBACTERIAL COMPOSITION AND EXTERNAL SKIN FORMULATION CONTAINING THE ANTIBACTERIAL COMPOSITION | |
| KR20170087469A (en) | Antiseptic composition and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140609 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150123 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150313 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150915 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151116 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160510 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160512 |
|
| R151 | Written notification of patent or utility model registration |
Ref document number: 5937321 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |